Physician profile
Emily E Sumner
NPI 1699069310
$2,403.77
in general payments reported to CMS, 2019-2025
25 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $109 · 2024: $673 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.32 | 2024-2025 | |
| Pfizer INC. | $320.54 | 2024-2025 | |
| Novo Nordisk INC | $300.96 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $289.29 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lundbeck LLC | $170.86 | 2024-2025 | Vyepti |
| Exact Sciences Corporation | $130.40 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Baxter Healthcare | $123.81 | 2022 | |
| Glaxosmithkline, LLC. | $110.62 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $96.40 | 2024-2025 | Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $90.64 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Amgen INC. | $58.54 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $44.48 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $44.42 | 2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.82 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $34.99 | 2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $30.43 | 2025 | |
| Tolmar, INC. | $28.93 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $26.41 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.56 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $21.40 | 2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $18.13 | 2024 | Nexletol |
| Axsome Therapeutics, INC. | $18.02 | 2025 | Auvelity |
| Seqirus USA INC | $17.49 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $16.16 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Sumner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.